MIAMI--(BUSINESS WIRE)--Biorasi, a leading global full-service contract research organization (CRO), is proud to announce the appointment of Alex A. Adjei, MD, PhD, FACP to the position of Scientific Advisory Board (SAB) member. In this role, Dr. Adjei will provide leadership and clinical expertise for oncology clinical studies and related areas at Biorasi.
“Dr. Adjei joining the Biorasi SAB team adds a new perspective in our approach to clinical trials for oncology and rare cancers,” noted Omar Ibrahim, PhD, Project Manager at Biorasi. “Additionally, his experience in Phase I and II trials builds upon our core competencies in speed, flexibility, and quality solutions.”
Dr. Adjei is one of four SAB members that have joined Biorasi in 2021. This esteemed group of clinicians and researchers includes experts in the fields of oncology, dermatology, hematology, and neurology, working together with Biorasi’s Board of Directors and company leadership.
Dr. Adjei is a consultant in Oncology, Professor of Oncology, and Professor of Pharmacology at the Mayo Clinic and Mayo College of Medicine in Rochester, MN. Dr. Adjei oversees oncology drug development as well as lung cancer research and treatment across all three Mayo Clinic sites, and is co-Leader of the Developmental Therapeutics program at Mayo Cancer Center. He has served as the PI on over 70 Phase I trials, as well as over 20 Phase II developmental trials for lung cancer therapy. Dr. Adjei received his MD from the University of Ghana and his PhD in Pharmacology from the University of Alberta, with an internal medicine residency at Howard University and a medical oncology fellowship at Johns Hopkins University.
“I am looking forward to working alongside Biorasi,” said Dr. Adjei. “This new role gives me the chance to add my oncology expertise and collaborate with other SAB members to promote innovation and evolution in clinical research.”
About Biorasi
Biorasi is a customer-focused, full-service, contract research organization (CRO) that delivers fast and flexible solutions across global clinical trials to maximize speed-to-market for its sponsors. As the leader in neurology, nephrology, dermatology, and the rare and urgent disease market, Biorasi sets new benchmarks for speed, agility, and quality in patient enrollment, decentralized trials, and data transparency. To learn more, contact Biorasi at info@biorasi.com / (786) 388-0700.
